Our Experience on Actovegin, is it Cutting Edge?

Cardiff University, Institute of Medical Engineering and Medical Physics, Cardiff, United Kingdom.
International Journal of Sports Medicine (Impact Factor: 2.37). 04/2011; 32(4):237-41. DOI: 10.1055/s-0030-1269862
Source: PubMed

ABSTRACT Muscle injuries are one of the most common sport related injuries, their incidence varying from 30-55% in all sports injuries. They account for the loss of 90 training days and 15 matches per club per season in elite football (soccer). In recent years, the use of Actovegin® in sports medicine has caused a lot of controversy in many sports disciplines. Although it is unlikely for this deproteinised substance to have oxygen-enhancing capacity, there is an anecdotal belief that Actovegin® can increase an athlete's performance. Actovegin® is produced by Nycomed Austria GmbH and has been used by doctors across Europe, China and Russia for over 60 years. Nevertheless, very little is known regarding the effects of Actovegin on muscle injuries. This article reviews the current evidence on Actovegin®, its legal status with sports governing bodies and its potential role in sport injuries. We will also report our experience with this drug in treating muscle injuries. In this pilot study, players in the Actovegin treatment group were able to return to play 8 days earlier (95% CI -1.249 to -14.7510) compared to physiotherapy alone (p=0.033). No adverse reactions were recorded in any of the participants.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Injection therapies are widely used for muscle injuries. As there is only limited evidence of their efficacy, physicians should be aware of the potential harmful effects of these injected preparations. The purpose of this review was to systematically review the literature on the myotoxic effects of intramuscular injection preparations commonly used for acute muscle injuries. The databases of PubMed, Embase, Web of Science, Cochrane Library, CINAHL and SportDiscus were searched in March 2013. Studies reporting histological evaluation or creatine kinase activity after intramuscular injection with local anaesthetics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), platelet-rich plasma (PRP), Traumeel(®) and Actovegin(®), or combination preparations were eligible for inclusion. Two authors independently screened the search results and assessed the risk of bias. A best-evidence synthesis was used to identify the level of evidence. Forty-nine studies were included in this systematic review. There is strong to moderate evidence that intramuscularly injected local anaesthetics and NSAIDs are myotoxic, and there is conflicting evidence of the myotoxicity of PRP. There is limited evidence that single corticosteroid injections are not myotoxic but have a synergistic myotoxic effect when used together with local anaesthetics. There is no information to assess whether Actovegin(®) and Traumeel(®) are myotoxic. Local anaesthetics and NSAID injections are not recommended for the treatment of muscle injuries in athletes, as they are myotoxic. The possible myotoxic effects of corticosteroids, PRP, Traumeel(®) and Actovegin(®) should be assessed in future research.
    04/2014; DOI:10.1007/s40279-014-0186-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Acute muscle belly injuries to the semitendinosus, semimembranosus and biceps femoris (the 'hamstring' muscles) remain a common problem in the sporting population. Physiotherapy-led rehabilitation remains the mainstay of treatment, and the physician's input is often minimal. Anecdotally, many different topical, oral and injectable therapies are used around the world in an effort to accelerate the healing of these injuries and to prevent their recurrence. This article reviews the evidence available to support some of the most commonly used medical therapies and the pathophysiological basis for their use. It also presents the evidence behind some of the more promising future treatments for muscle injury, including stem cell therapy, growth factor delivery and potential novel uses of current medication not traditionally used in the musculoskeletal setting.
    01/2014; 14(7). DOI:10.1080/17461391.2013.878756
  • [Show abstract] [Hide abstract]
    ABSTRACT: Muscle strain injuries remain one of the most common injuries in sport, with a significant morbidity for elite and non-elite athletes.1 The past 25 years has seen a significant increase in our understanding of the epidemiology and pathophysiology of this injury. While prevention of muscle injuries remains the Holy Grail and is appropriately attracting significant research activity, we are yet to observe a sustained reduction in the incidence of muscle injuries in elite sport.1 Furthermore, despite the high prevalence of muscle injuries, there remains limited research into the best management of muscle strain injuries2; research has typically been limited to low-level studies3 and considered analogous to ‘snake-oil’. Since the 1990s, solutions of concentrated platelets derived from the manipulation of autologous blood, in the form of platelet rich plasma (PRP), have been used to enhance healing of a range of medical conditions.4 PRP is alleged to facilitate muscle healing through the optimised provision of … [Full text of this article]
    British Journal of Sports Medicine 07/2014; 48(18). DOI:10.1136/bjsports-2014-094009 · 4.17 Impact Factor